In-depth virological assessment of kidney transplant recipients with COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.06.17.20132076: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol was reviewed and approved by the local Institutional Review Board (approval number: DC-2013-1990). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 4 2.3 SARS-CoV-2 serological assessment: Immunoglobulin (Ig) M and IgG antibody responses to SARS-CoV-2 recombinant nucleocapsid and spike antigens were tested using a commercially available enzyme-linked immunosorbent assay (ELISA; DIA.PRO Diagnostic BioProbes 4 2.3 SARS-CoV-2 serological assessment: Immunoglobulin (Ig) Msuggested: NoneIgG antibody responses to SARS-CoV-2 …SciScore for 10.1101/2020.06.17.20132076: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol was reviewed and approved by the local Institutional Review Board (approval number: DC-2013-1990). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 4 2.3 SARS-CoV-2 serological assessment: Immunoglobulin (Ig) M and IgG antibody responses to SARS-CoV-2 recombinant nucleocapsid and spike antigens were tested using a commercially available enzyme-linked immunosorbent assay (ELISA; DIA.PRO Diagnostic BioProbes 4 2.3 SARS-CoV-2 serological assessment: Immunoglobulin (Ig) Msuggested: NoneIgG antibody responses to SARS-CoV-2 recombinant nucleocapsid and spike antigenssuggested: NoneSoftware and Algorithms Sentences Resources Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Inc., San Diego, CA, USA). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Despite some limitations of this study, including the small sample size and lack of data from some patients, this is the first report that provides a precise assessment of SARS-CoV-2 virological and antibody response kinetics in an immunocompromised population, with a follow-up for two months after symptom onset. Taken together, our data indicate that 1) SARS-CoV-2 shedding from the upper respiratory tract is prolonged in KTR patients, indicating the requirement for prolonged protective measures for these patients; 2) the SARS-CoV-2 plasma load is associated with COVID-19 severity and mortality, whereas the viral load of the upper respiratory tract is not; and 3) based on the presence of antibodies in all samples collected by us after the second week of symptom onset, the SARS-CoV-2 humoral response in our immunocompromised population does not show serious impairment and the antibodies persist until two months after COVID-19 symptom onset.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-